Biomarkers in osteoarthritis: current status and outlook - the FNIH Biomarkers Consortium PROGRESS OA study.
Skeletal Radiol
; 52(11): 2323-2339, 2023 Nov.
Article
em En
| MEDLINE
| ID: mdl-36692532
ABSTRACT
Currently, no disease-modifying therapies are approved for osteoarthritis (OA) use. One obstacle to trial success in this field has been our existing endpoints' limited validity and responsiveness. To overcome this impasse, the Foundation for the NIH OA Biomarkers Consortium is focused on investigating biomarkers for a prognostic context of use for subsequent qualification through regulatory agencies. This narrative review describes this activity and the work underway, focusing on the PROGRESS OA study.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteoartrite
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Skeletal Radiol
Ano de publicação:
2023
Tipo de documento:
Article